Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
The Oncologist|September 5, 2020
Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic DirectionsDenis L Jardim, Sherri Z Millis, Jeffrey S Ross, et al.
The Oncologist|February 1, 2021
Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted TherapeuticsDenis L Jardim, Sherri Z Millis, Jeffrey S Ross, et al.
Cancer|December 25, 2018
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunitiesSherri Z Millis, Denis L Jardim, Lee Albacker, et al.
The Journal of Infectious Diseases|March 5, 2004
Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?Mitzi G Mendonça, Maria E F de Brito, Eduardo H G Rodrigues, et al.
Revista Do Instituto De Antibioticos, Universidade Federal De Pernambuco|December 1, 1974
[First observations on the topical use of Primin, Plumbagin and Maytenin in patients with skin cancer]A M Melo, M L Jardim, C F De Santana, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 2, 2015
The molecular basis of low activity levels of coagulation factor VII: a Brazilian cohortF Y Rabelo, L L Jardim, M B Landau, et al.
Memorias Do Instituto Oswaldo Cruz|July 1, 1994
Exploitation of parasite derived antigen in therapeutic success of human cutaneous leishmaniasis in BrazilL Monjour, A B Neogy, I Vouldoukis, et al.
Journal of Inherited Metabolic Disease|May 26, 2004
CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapyL Jardim, L Vedolin, I V D Schwartz, et al.
The Oncologist|April 26, 2025
Identifying predictors of overall survival among patients with TMB-low metastatic cancer treated with immune checkpoint inhibitorsCamila Braganca Xavier, Gabriela D A Guardia, João Pedro B Alves, et al.
Journal of the National Cancer Institute|September 18, 2015
Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA ApprovalDenis L Jardim, Denis L Fontes Jardim, Maria Schwaederle, et al.
Pageof 5